The invention provides compositions, formulations, and methods for treatment of malignancies via activation of an inflammatory response in the subject. Such compositions, formulations, and methods for are preferably used in conjunction with other therapies for the treatment and/or management of malignancies, e.g., chemotherapy and/or radiation. The invention also provides methods of monitoring immune activation in subjects with malignancies.

Aspects of the present invention relate to the assessment of explant organ viability prior to transplantation. Particularly, although not exclusively, aspects of the present invention relate to biomarkers which can be used to inform a decision as to whether an organ is suitable for transplantation into a recipient. In certain embodiments, the organ is undergoing hypothermic perfusion following retrieval from a donor.

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

The present disclosure relates generally to compositions and methods for identifying cell therapy patients as being likely or not likely to experience toxicity following the cell therapy. The methods are based on the discovery that pre-treatment covariates, such as serum IL-15 and MCP-1 levels in the patients or the viability of the cells being administered can be used predict the likelihood of the onset of such toxicities. Once the patient is identified as being likely or not likely to experience the toxicities, compositions and methods are also provided for monitoring and managing the toxicities.

Recombinant antibodies that specifically bind to IL-15 as well as a complex of IL-15 and the IL-15 Receptor-alpha are provided. The antibodies inhibit immune cell proliferation, and are capable of use in the treatment of any autoimmune or inflammatory disease or condition where IL-15 is dysregulated, including Celiac disease.

Biomarker panels for the prediction of patient response to immunotherapy, and methods of use thereof.

The invention provides methods of increasing the efficacy of a T cell therapy in a patient in need thereof. The invention includes methods of identifying a patient who would respond well to a T cell therapy or conditioning a patient prior to a T cell therapy so that the patient responds well to a T cell therapy. The conditioning involves administering one or more preconditioning agents prior to a T cell therapy and identifying biomarker cytokines prior to administering a T cell therapy.

Provided herein, are methods and compositions for detecting heteromeric protein complexes in biological samples. The methods and compositions allow for capturing and detecting the protein complex with substantially the same antibody, while avoiding detection of native proteins.

Methods and compositions related to the selective, specific disruption of multiple ligand-receptor signaling interactions, such as ligand-receptor interactions implicated in disease, are disclosed. These interactions may involve multiple cytokines in a single receptor family or multiple ligand receptor interactions from at least two distinct ligand-receptor families. The compositions may comprise polypeptides having composite sequences that comprise sequence fragments of two or more ligand binding sites. The methods and compositions may involve sequence fragments of two or more ligand binding sites that are arranged to conserve the secondary structure of each of the ligands from which the sequence fragments were taken.

A recombinant deamidated gliadin polypeptide antigen, a recombinant antigen-expressing gene, a recombinant expression vector, a preparation method therefor, and an application thereof. The recombinant deamidated gliadin polypeptide antigen comprises a DGP-1 peptide, an interleukin 15 protein, and a DGP-2 peptide. The amino acid sequence of the DGP-1 peptide is as shown in SEQ ID NO. 1, and the amino acid sequence of the DGP-2 peptide is as shown in SEQ ID NO 2. The recombinant deamidated gliadin polypeptide antigen has good sensitivity, high specificity, and low preparation costs in the detection of celiac disease, allows determination of IgG-DGP antibodies in serum, and especially enables diagnosis for potential patients with celiac disease among patients with IgA deficiency and infant population.